CryoCell Competitors
| CCEL Stock | USD 3.32 0.11 3.21% |
CryoCell International vs Rockwell Medical Correlation
Average diversification
The correlation between CryoCell International and RMTI is 0.1 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding CryoCell International and RMTI in the same portfolio, assuming nothing else is changed.
Moving together with CryoCell Stock
Moving against CryoCell Stock
| 0.86 | SPGX | Sustainable Projects | PairCorr |
| 0.84 | CUEN | Cuentas | PairCorr |
| 0.83 | BTSG | BrightSpring Health | PairCorr |
| 0.75 | SLB | Schlumberger NV Sell-off Trend | PairCorr |
| 0.74 | H | Hyatt Hotels | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of CryoCell International's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
CryoCell International Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between CryoCell International and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of CryoCell and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of CryoCell International does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between CryoCell Stock performing well and CryoCell International Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze CryoCell International's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ZYXI | 13.90 | (2.63) | 0.00 | (0.39) | 0.00 | 29.17 | 163.35 | |||
| JSPR | 4.27 | (0.54) | 0.00 | (13.93) | 0.00 | 7.73 | 31.75 | |||
| NMTC | 3.62 | 0.11 | 0.04 | 0.08 | 3.81 | 9.59 | 23.46 | |||
| YI | 4.79 | 1.01 | 0.22 | 11.22 | 3.91 | 15.20 | 47.07 | |||
| PIII | 3.58 | (2.23) | 0.00 | (1.62) | 0.00 | 6.04 | 25.37 | |||
| MURA | 0.38 | (0.04) | 0.00 | (0.10) | 0.00 | 0.96 | 4.78 | |||
| ATHE | 3.14 | (0.54) | 0.00 | (0.21) | 0.00 | 5.71 | 17.55 | |||
| EVAX | 4.43 | (0.80) | 0.00 | 1.22 | 0.00 | 9.15 | 37.88 | |||
| LIMN | 5.37 | (0.93) | 0.00 | 16.84 | 0.00 | 10.11 | 53.06 | |||
| RMTI | 3.75 | 0.06 | 0.00 | (0.14) | 4.01 | 6.38 | 40.19 |
Cross Equities Net Income Analysis
Compare CryoCell International and related stocks such as Zynex Inc, Jasper Therapeutics, and Neuroone Medical Tec Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZYXI | (91.3 K) | 1.6 M | 1.6 M | (7.3 M) | (6.2 M) | (2.9 M) | 69 K | 7.4 M | 9.6 M | 9.5 M | 9.1 M | 17.1 M | 17 M | 9.7 M | 3 M | 3.4 M | 2.8 M |
| JSPR | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (31.7 M) | (30.6 M) | (37.7 M) | (64.5 M) | (71.3 M) | (64.1 M) | (67.3 M) |
| NMTC | (6 K) | (14 K) | (14 K) | (30.6 K) | (36.2 K) | (62.9 K) | (47.8 K) | (6.8 M) | (6.8 M) | (13.6 M) | (9.9 M) | (10 M) | (11.9 M) | (12.3 M) | (3.6 M) | (3.2 M) | (3.4 M) |
| YI | (362.7 M) | (362.7 M) | (362.7 M) | (362.7 M) | (362.7 M) | (362.7 M) | (362.7 M) | (248.6 M) | (380.1 M) | (501.8 M) | (456.5 M) | (669.8 M) | (416.9 M) | (392.7 M) | (64.7 M) | (74.5 M) | (78.2 M) |
| PIII | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (42 M) | (31.4 M) | (270.1 M) | (270.1 M) | (57.8 M) | (135.8 M) | (122.3 M) | (128.4 M) |
| ATHE | (690) | (5.2 M) | (7.8 M) | (13.3 M) | (5.9 M) | (7.7 M) | (7.5 M) | (8.3 M) | (12 M) | (10.1 M) | (15.3 M) | (12.8 M) | (13.8 M) | (19.1 M) | (12.1 M) | (10.9 M) | (11.5 M) |
| EVAX | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (11.2 M) | (15 M) | (24.5 M) | (23.2 M) | (22.1 M) | (10.6 M) | (9.5 M) | (10 M) |
| LIMN | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | (2.9 M) | (1.2 M) | (2.9 M) | (2.6 M) | (2.5 M) |
| RMTI | (1.9 M) | (21.4 M) | (54 M) | (48.8 M) | (21.3 M) | (14.4 M) | (19.8 M) | (25.9 M) | (32.1 M) | (34.1 M) | (30.9 M) | (32.7 M) | (18.7 M) | (8.4 M) | (480 K) | (432 K) | (453.6 K) |
CryoCell International and related stocks such as Zynex Inc, Jasper Therapeutics, and Neuroone Medical Tec Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in CryoCell International financial statement analysis. It represents the amount of money remaining after all of CryoCell International operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.CryoCell International Competitive Analysis
The better you understand CryoCell International competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, CryoCell International's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across CryoCell International's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
CryoCell International Competition Performance Charts
Five steps to successful analysis of CryoCell International Competition
CryoCell International's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by CryoCell International in relation to its competition. CryoCell International's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of CryoCell International in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact CryoCell International's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to CryoCell International, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your CryoCell International position
In addition to having CryoCell International in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Diversified Assets Thematic Idea Now
Diversified Assets
Pablicly traded close-end funds and other entities backed by different types of diversified investments. The Diversified Assets theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Diversified Assets Theme or any other thematic opportunities.
| View All Next | Launch |
Check out CryoCell International Correlation with its peers. For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CryoCell International. Projected growth potential of CryoCell fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive CryoCell International assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.31) | Dividend Share 0.65 | Earnings Share (0.06) | Revenue Per Share | Quarterly Revenue Growth (0.03) |
Investors evaluate CryoCell International using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating CryoCell International's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause CryoCell International's market price to deviate significantly from intrinsic value.
It's important to distinguish between CryoCell International's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CryoCell International should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, CryoCell International's market price signifies the transaction level at which participants voluntarily complete trades.